Amylyx Pharmaceuticals (NASDAQ:AMLX) vs. Abeona Therapeutics (NASDAQ:ABEO) Head to Head Review

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, analyst recommendations, valuation and risk.

Volatility & Risk

Amylyx Pharmaceuticals has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Earnings & Valuation

This table compares Amylyx Pharmaceuticals and Abeona Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amylyx Pharmaceuticals $87.37 million 38.79 -$144.74 million ($1.44) -18.31
Abeona Therapeutics $5.82 million 26.46 $71.18 million ($1.07) -2.52

Abeona Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Amylyx Pharmaceuticals and Abeona Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amylyx Pharmaceuticals 1 0 6 2 3.00
Abeona Therapeutics 1 0 5 0 2.67

Amylyx Pharmaceuticals presently has a consensus target price of $43.71, indicating a potential upside of 65.84%. Abeona Therapeutics has a consensus target price of $21.00, indicating a potential upside of 679.22%. Given Abeona Therapeutics’ higher possible upside, analysts clearly believe Abeona Therapeutics is more favorable than Amylyx Pharmaceuticals.

Insider and Institutional Ownership

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are held by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Amylyx Pharmaceuticals and Abeona Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amylyx Pharmaceuticals N/A -41.54% -38.91%
Abeona Therapeutics -160.30% -44.82% -32.51%

Summary

Amylyx Pharmaceuticals beats Abeona Therapeutics on 9 of the 15 factors compared between the two stocks.

About Amylyx Pharmaceuticals

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.